ESR1 and breast cancer: In aggregate, our RNA-seq and ATAC-seq data indicate that ER+ breast cancer cells are poised for an enhanced response to IFNγ after ER blockade, and IFNγ stimulation leads to an enhanced downstream response in HD conditions.